Content Status

Type

Linked Node

H5Content
Content

Adverse Drug Reactions (ADRs), such as gastritis and abdominal pain, may occur from the Drug-resistant TB (DR-TB) treatment regimen.

Suspected agent(s): Para Aminosalicylic Acid (PAS), Ethionamide (Eto), Clofazimine (Cfz), Linezolid (Lzd), Fluoroquinolone (FQs), Isoniazid (H), Ethambutol (E), and Pyrazinamide (Z)

  • Abdominal pain is often associated with serious adverse effects, such as pancreatitis {Lzd, Bedaquiline (Bdq)}, lactic acidosis and hepatitis. 
  • If any of these are suspected, it is important to obtain appropriate laboratory tests to confirm and suspend the suspected agent.

Suggested Management Strategies

  • For gastritis-like symptoms (epigastric burning or discomfort, sour taste in mouth associated with reflux) initiate medical treatment with the use of H2-blockers (Ranitidine 150 mg twice daily or 300 mg once daily).
  • Proton-pump inhibitors (Omeprazole 20 mg once daily) should be avoided along with Bdq.
  • Avoid use of antacids as they decrease absorption of FQ.
  • For severe abdominal pain, stop suspected agent(s) for short periods of time (1-7 days).
  • Lower the dose of the suspected agent or discontinue, if this can be done without compromising the regimen.

Points to Note

  • Severe gastritis, as manifested by blood in the vomit or stool, is relatively rare but should always be treated to facilitate adherence to treatment.
  • If antacids must be used, they should be carefully timed to not interfere with absorption of FQ (take two hours before or three hours after anti-TB drugs).
  • Stop any non-steroidal anti-inflammatory drugs the patient may be taking.
  • Diagnose and treat Helicobacter pylori infections.
  • Severe abdominal distress has been reported with the use of Cfz. Although these reports are rare, if this occurs, Cfz should be suspended.

 

Resources

 

Kindly provide your valuable feedback on the page to the link provided HERE

Content Creator

Reviewer